Rua Bioscience Limited Analysis

Overview

Rua is a New Zealand pharmaceutical company that is aiming to be a leading producer of cannabinoid derived medicines. The Company was established in 2017 in part to support local economic development in the Tairāwhiti (East Coast) region, and is a pioneer in the New Zealand medicinal cannabis sector. It was the first company in New Zealand to obtain a licence to cultivate cannabis for research purposes and the Company’s co-founder was actively involved in both the establishment of the key industry association and the development of the regulatory framework that is now in place to govern the sector. Rua will operate in the research, cultivation, extraction and manufacturing parts of the medicinal cannabis supply chain.

Performance

The following information has been extracted from Rua Bioscience Limited's full year results, released on 1 September 2025:

Summary financials

Revenue from customers

FY25 $1,511,282

FY24 $85,837

Total revenue and other income

FY25 $1,899,733

FY24 $321,678

Loss before impairment

FY25 ($3,419,401)

FY24 ($4,504,779)

Loss before tax

FY25 ($3,455,661)

FY24 ($13,718,754)

FY25 milestones

• Delivered strong revenue growth across all three key markets.

• Expanded the German product portfolio at a pivotal point in the market.

• Secured alignment with leading clinic chains in Australia to drive revenue.

• Broadened the product range in Aotearoa, New Zealand.

• Established a new UK sales pipeline in partnership with Target Healthcare.

• Launched a new product in Australia leveraging legacy genetics.

• Successfully raised $1.50 mill from shareholders to accelerate growth.